Modified gemcitabine, S-1, and leucovorin combination for patients with newly diagnosed locally advanced or metastatic pancreatic adenocarcinoma: A multi-center retrospective study in Taiwan

BACKGROUND: In pancreatic cancer, toxicities associated with current chemotherapeutic regimens remain concerning. A modified combination of gemcitabine, S-1, and leucovorin (GSL) was used as the first-line treatment for newly diagnosed locally advanced or metastatic pancreatic adenocarcinoma patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Chia-Yu, Liang, Shih-Hsin, Su, Yung-Yeh, Chiang, Nai-Jung, Wang, Hui-Ching, Chiu, Chang-Fang, Chen, Li-Tzong, Bai, Li-Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7771868/
https://www.ncbi.nlm.nih.gov/pubmed/33373398
http://dx.doi.org/10.1371/journal.pone.0244487

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7771868/
https://www.ncbi.nlm.nih.gov/pubmed/33373398
http://dx.doi.org/10.1371/journal.pone.0244487

Ejemplares similares